Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/21/21 (What's New)

Summary

  • Two agents are approved for use in combination with other ARV agents in heavily treatment–experienced patients with multidrug resistance who are experiencing failure of their current ART regimen
    • Ibalizumab-uiyk: postattachment inhibitor approved by the FDA in 2018
    • Fostemsavir: attachment inhibitor approved by the FDA in 2020

Action required